Turn Therapeutics Inc. (TTRX) Stock Price & Analysis
Turn Therapeutics Inc. (TTRX) rose 9.40% to USD 5.53 as of June 11, 2026 at 07:24 UTC, according to Nexqual real-time market data.
TTRX last closed at USD 5.06; the session ranged USD 5.06–5.97 on volume of 60,963 shares. Market capitalization is $164.73M, with a 52-week range of USD 2.57–26.5 (NGM). Source: Nexqual, June 11, 2026 at 07:24 UTC.
Key Statistics (as of June 11, 2026 at 07:24 UTC)
| Price | USD 5.53 |
|---|---|
| Change | ▲ 9.40% (up) |
| Previous Close | USD 5.06 |
| Open | USD 5.06 |
| Day Range | USD 5.06 – 5.97 |
| 52-Week Range | USD 2.57 – 26.5 |
| Volume | 60,963 shares |
| Market Cap | $164.73M |
| Exchange | NGM |
Technical Analysis (TTRX)
Nexqual's technical model rates TTRX "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 11, 2026 at 07:24 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.3 (neutral) |
| vs SMA50 | Above (USD 4.13) |
| MACD | 0.43 (positive) |
Analyst Ratings (TTRX)
Wall Street analysts rate TTRX "None", per Nexqual as of June 11, 2026 at 07:24 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (TTRX)
| Next Earnings Date | 2026-05-11 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est -0.02 ▼ miss |
Source: Nexqual, June 11, 2026 at 07:24 UTC.
Financials & Fundamentals (TTRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -129.17% |
| Debt / Equity | 98.17 |
| Current Ratio | 2.23 |
| Total Cash | $11.22M |
| Total Debt | $6.01M |
Source: Nexqual, June 11, 2026 at 07:24 UTC.
Financial Health Score (TTRX)
Nexqual rates Turn Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 11, 2026 at 07:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $11M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -129% |
Ownership (TTRX)
| Insider Ownership | +63.74% |
|---|---|
| Institutional Ownership | +1.74% |
| Shares Outstanding | 29.79M |
| Float | 10.83M |
Source: Nexqual, June 11, 2026 at 07:24 UTC.
Leadership (TTRX)
Turn Therapeutics Inc. is led by Bradley E. Burnam (age 45), Founder, CEO & Director, per Nexqual as of June 11, 2026 at 07:24 UTC.
| Founder, CEO & Director | Bradley E. Burnam (age 45) |
|---|---|
| Interim CFO, VP of Finance & Chief Accounting Officer | Zuraiz Chaudhary (age 29) |
| Chief Medical Officer & Director | Neilesh Shailesh Ghodadra (age 44) |
Major Backers & Investors (TTRX)
Notable institutional backers of Turn Therapeutics Inc. include Ddfg, Inc , Millennium Management, Wellington Management, according to Nexqual as of June 11, 2026 at 07:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ddfg, Inc | 0.24% |
| Millennium Management | 0.23% |
| Wellington Management | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.33% |
Source: Nexqual, June 11, 2026 at 07:24 UTC.
From Turn Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
- The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRB | Spruce Biosciences, Inc. | USD 47.13 | ▼ 4.44% |
| LFS | LEIFRAS Co., Ltd. | USD 1.96 | ▼ 0.51% |
| YDDL | One and One Green Technologies. | USD 2.85 | ▲ 14% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 7.42 | ▲ 9.12% |
| YOOV | Concorde International Group Lt | USD 0.48 | ▼ 14.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 07:24 UTC. This page is informational and not investment advice.